Alpha 1-antitrypsin deficiency future or investigational therapies: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(17 intermediate revisions by 5 users not shown)
Line 1: Line 1:
__NOTOC__
{{Alpha 1-antitrypsin deficiency}}
{{Alpha 1-antitrypsin deficiency}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}
{{CMG}}; '''Associate Editor-In-Chief:'''{{Mazia}}


==Overview==
==Overview==
Alpha 1-antitrypsin deficiency (A1AD) is currently being investigated for the prevention of polymer formation in the liver.
Treatment options of alpha 1-antitrypsin deficiency currently being studied include [[recombination]] and [[Inhalants|inhaled]] forms of Alpha 1-antitrypsin. Other experimental therapies are aimed at the [[prevention]] of [[polymer]] formation in the [[liver]]. [[Gene therapy]] to deliver [[recombinant]] [[adeno-associated virus]] carrying the [[human]] AAT gene is also being investigated as a alternate treatment approach.


==Future or Investigational Therapies==
==Future or Investigational Therapies==
Treatments currently being studied include recombinant and inhaled forms of A1AT. Other experimental therapies are aimed at the prevention of [[polymer]] formation in the [[liver]].
[[Treatments]] currently being studied include [[recombination]] and inhaled forms of Alpha 1-antitrypsin. Other experimental therapies are aimed at the prevention of [[polymer]] formation in the [[liver]]. Newer treatment strategies include:<ref name="pmid23771682">{{cite journal |vauthors=Turner AM |title=Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies |journal=BioDrugs |volume=27 |issue=6 |pages=547–58 |year=2013 |pmid=23771682 |doi=10.1007/s40259-013-0042-5 |url=}}</ref>
*[[Gene therapy]] to deliver [[recombinant]] [[adeno-associated virus]] carrying the human [[Alpha 1-antitrypsin|Alpha 1-antitrypsin gene]].
*[[Inhibition]] of intrahepatic [[polymerization]] of [[alpha 1-antitrypsin]].
*Promotion of hepatic secretion of [[AAT]].
*[[Pegylation]] to prolong the serum half-life of [[AAT]].
*[[Inhalation]] of [[AAT]] that results in complete [[inhibition]] of [[neutrophil elastase]] activity and marked reduction in [[elastin]] [[degradation]].
*Small interfering [[RNA]] that interferes with [[AAT]] production.
*[[Carbamazepine]] or [[Rapamycin]] can be used to enhance intrahepatic [[degradation]] of [[mutant]] [[AAT]] by [[autophagy]].  


'''Pitfalls of Therapy:'''
===Pitfalls of Therapy===
* Despite the isolation and cloning of the alpha-1 AT gene, the efficacy of augmentation therapy remains controversial due to the lack of large randomized trials that define the treatment regimens and target population. The current goal of therapy is to raise the level of alpha-1 AT in the plasma, and therefore the lung interstitium above the ‘protective’ threshold of 11 umol/L (80 mg/dl).  There are basically two types of treatment for this disease, ''augmentation'' therapy, and organ transplantation.
* Despite the [[Isolation (health care)|isolation]] and [[cloning]] of the alpha-1 AT [[gene]], the efficacy of augmentation therapy remains controversial due to the lack of [[Randomized trial|large randomized trials]] that define the [[Treatments|treatment]] regimens and target [[population]].  
* Endogenous enhancement of alpha-1 AT production has been attempted pharmacologically with medications such as Danazol, Tamoxifen and estrogen/progesterone combinations based on the observation that alpha-1 AT levels increase as an acute phase reactant in times of stress (including pregnancy).  Unfortunately, the alpha-1 AT levels do not increase enough to warrant therapy.
* The current goal of [[therapy]] is to raise the level of alpha-1 AT in the [[plasma]] above the ‘threshold of 11 umol/L (80 mg/dl).  There are basically two types of [[Treatments|treatment]] for this [[disease]], ''augmentation'' [[therapy]], and [[Organ (biology)|organ]] [[transplantation]].
* Exogenous augmentation via aerosolization of either pooled human alpha-1 AT, or recombinant alpha-1 AT has been attempted, and both are thought to be safe and effective.  Large clinical trials are currently underway.
* Endogenous enhancement of alpha-1 AT production has been attempted pharmacologically with [[medications]] such as [[Danazol]], [[Tamoxifen]] and [[estrogen]]/[[progesterone]] combinations based on the observation that alpha-1 AT levels increase as an [[acute phase reactant]] in times of [[stress]] (including [[pregnancy]]).  Unfortunately, the alpha-1 AT levels do not increase enough to warrant therapy.
* Gene therapy uses viruses that have been altered so they can not replicate to ‘infect’ and integrate their genome (with the cDNA of alpha-1 AT) into host cells with the goal of the host cell manufacturing endogenous alpha-1 AT.   Unfortunately, in the initial studies, expression of the gene was limited, and the alpha-1 AT levels did not increase above the protective threshold.
* Exogenous augmentation via aerosolization of either pooled [[human]] alpha-1 AT, or [[recombinant]] alpha-1 AT has been attempted, and both are thought to be safe and effective.  Large [[clinical]] trials are currently underway.
* Exogenous augmentation via IV infusion of pooled human alpha-1 AT is the only approved method of augmentation therapy for patients with alpha-1 AT deficiency.  Although being safe, well-tolerated, and without significant side effects, its clinical efficacy is still unproven.  In addition, the goal plasma level is not known, especially since there is a cohort of patients with severe alpha-1 AT deficiency that are not symptomatic.  Unfortunately, there has not been a randomized, double-blinded, placebo-controlled trial in patients with alpha-1 AT deficiency with and without symptoms.
* [[Gene therapy]] uses [[viruses]] that have been altered so they can not replicate to infect and integrate their [[genome]] (with the [[cDNA]] of alpha-1 AT) into [[Hosts|host]] [[cells]] with the goal of the [[Hosts|host]] [[cell]] manufacturing [[endogenous]] alpha-1 AT. Unfortunately, in the initial studies, [[expression]] of the [[gene]] was limited, and the alpha-1 AT levels did not increase above the protective threshold.
*:* A recent observational study compared the rate of decline in FEV1 in 97 Danish ex-smokers to 198 German ex-smokers, both of whom had severe alpha-1 AT deficiency.  The German subjects received weekly infusions of 60 mg/kg alpha-1 AT, and the Danish did not receive augmentation therapy.  The Germans had a slower rate of decline in their FEV1 as compared with the Danes (-53 ml/yr vs. -75 ml/yr, p=0.002).
* [[Exogenous]] augmentation via IV infusion of pooled [[human]] alpha-1 AT is the only approved method of augmentation [[therapy]] for [[patients]] with alpha-1 AT deficiency.  Although being safe, well-tolerated, and without significant [[side effects]], its [[clinical]] efficacy is still unproven.  In addition, the goal [[Plasma|plasma level]] is not known, especially since there is a [[cohort]] of [[patients]] with severe alpha-1 AT deficiency that are not symptomatic.  Unfortunately, there has not been a [[randomized]], double-blinded, [[placebo]]-controlled trial in [[patients]] with alpha-1 AT deficiency with and without [[symptoms]].
*:* Although weekly infusions are the only FDA approved regimen, monthly infusions (250 mg/kg) seem to have the same efficacy and safety and are widely used.
*:* A recent observational study compared the rate of decline in [[FEV1]] in 97 Danish ex-smokers to 198 German ex-smokers, both of whom had severe alpha-1 AT deficiency.  The German subjects received weekly infusions of 60 mg/kg alpha-1 AT, and the Danish did not receive augmentation therapy.  The Germans had a slower rate of decline in their [[FEV1]] as compared with the Danes (-53 ml/yr vs. -75 ml/yr, p=0.002).
*:* The ATS recommends augmentation therapy for patients with alpha-1 AT phenotypes PI ZZ, PI Z null or PI null null with alpha-1 AT levels < 11 umol/L and airflow obstruction.  Conversely, the Canadian Thoracic Society recommends waiting until the results of a large trial establish its efficacy.  Additionally, although it is thought that severe COPD is associated with negligible benefit, a lower limit of FEV1 below which augmentation therapy should be withheld has not been proposed.
*:* Although weekly infusions are the only [[FDA]] approved regimen, monthly infusions (250 mg/kg) seem to have the same [[efficacy]] and safety and are widely used.
*:* It is crucial that these patients don’t smoke, and are treated with bronchodilators, just as other patients with airways obstruction.  They should also receive pneumococcal and influenza vaccines.
*:* The ATS recommends augmentation therapy for [[patients]] with alpha-1 AT [[phenotypes]] PI ZZ, PI Z null or PI null null with alpha-1 AT levels < 11 umol/L and airflow obstruction.   
*:* It is crucial that these [[patients]] don’t [[smoke]], and are treated with [[bronchodilators]], just as other [[patients]] with [[airways]] [[obstruction]].  They should also receive [[pneumococcal]] and [[influenza]] [[vaccines]].
*:* A years worth of IV augmentation therapy costs approximately $25,000 - $35,000 (90% of which is for the drug).
*:* A years worth of IV augmentation therapy costs approximately $25,000 - $35,000 (90% of which is for the drug).
*:* There have not been any cases of HIV or hepatitis transmitted by pooled human alpha-1 AT.
*:* There have not been any cases of [[HIV]] or [[hepatitis]] transmitted by pooled [[human]] alpha-1 AT.
*:* Transplantation of both lungs and liver has been offered to patients with end stage disease.  Liver transplantation has the added benefit of correcting the underlying disorder, as the new liver will produce and secrete alpha-1 AT.  There is no data to support the use of augmentation therapy after lung transplantation, although some authors suggest augmentation therapy during times of increased neutrophil burden in the lung.
*:* [[Transplantation]] of both [[lungs]] and [[liver]] has been offered to [[patients]] with end stage [[disease]][[Liver]] [[transplantation]] has the added benefit of correcting the underlying [[disorder]], as the new [[liver]] will produce and secrete alpha-1 AT.  There is no data to support the use of augmentation [[therapy]] after [[lung]] [[transplantation]], although some authors suggest augmentation [[therapy]] during times of increased [[neutrophil]] burden in the [[lung]].


==References==
==References==
Line 26: Line 35:


[[Category:Gastroenterology]]
[[Category:Gastroenterology]]
[[Category:Genetic disorders]]
[[Category:Pulmonology]]
[[Category:Pulmonology]]
[[Category:Hepatology]]
[[Category:Hepatology]]
[[Category:Inborn errors of metabolism]]
[[Category:Metabolic disorders]]
[[Category:Mature chapter]]
[[Category:Disease state]]


{{WikiDoc Help Menu}}
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}
{{WikiDoc Sources}}

Latest revision as of 05:23, 6 January 2018

Alpha 1-antitrypsin deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Alpha 1-antitrypsin deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Alpha 1-antitrypsin deficiency future or investigational therapies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Alpha 1-antitrypsin deficiency future or investigational therapies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Alpha 1-antitrypsin deficiency future or investigational therapies

CDC on Alpha 1-antitrypsin deficiency future or investigational therapies

Alpha 1-antitrypsin deficiency future or investigational therapies in the news

Blogs on Alpha 1-antitrypsin deficiency future or investigational therapies

Directions to Hospitals Treating Alpha 1-antitrypsin deficiency

Risk calculators and risk factors for Alpha 1-antitrypsin deficiency future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief:Mazia Fatima, MBBS [2]

Overview

Treatment options of alpha 1-antitrypsin deficiency currently being studied include recombination and inhaled forms of Alpha 1-antitrypsin. Other experimental therapies are aimed at the prevention of polymer formation in the liver. Gene therapy to deliver recombinant adeno-associated virus carrying the human AAT gene is also being investigated as a alternate treatment approach.

Future or Investigational Therapies

Treatments currently being studied include recombination and inhaled forms of Alpha 1-antitrypsin. Other experimental therapies are aimed at the prevention of polymer formation in the liver. Newer treatment strategies include:[1]

Pitfalls of Therapy

  • Despite the isolation and cloning of the alpha-1 AT gene, the efficacy of augmentation therapy remains controversial due to the lack of large randomized trials that define the treatment regimens and target population.
  • The current goal of therapy is to raise the level of alpha-1 AT in the plasma above the ‘threshold of 11 umol/L (80 mg/dl). There are basically two types of treatment for this disease, augmentation therapy, and organ transplantation.
  • Endogenous enhancement of alpha-1 AT production has been attempted pharmacologically with medications such as Danazol, Tamoxifen and estrogen/progesterone combinations based on the observation that alpha-1 AT levels increase as an acute phase reactant in times of stress (including pregnancy). Unfortunately, the alpha-1 AT levels do not increase enough to warrant therapy.
  • Exogenous augmentation via aerosolization of either pooled human alpha-1 AT, or recombinant alpha-1 AT has been attempted, and both are thought to be safe and effective. Large clinical trials are currently underway.
  • Gene therapy uses viruses that have been altered so they can not replicate to infect and integrate their genome (with the cDNA of alpha-1 AT) into host cells with the goal of the host cell manufacturing endogenous alpha-1 AT. Unfortunately, in the initial studies, expression of the gene was limited, and the alpha-1 AT levels did not increase above the protective threshold.
  • Exogenous augmentation via IV infusion of pooled human alpha-1 AT is the only approved method of augmentation therapy for patients with alpha-1 AT deficiency. Although being safe, well-tolerated, and without significant side effects, its clinical efficacy is still unproven. In addition, the goal plasma level is not known, especially since there is a cohort of patients with severe alpha-1 AT deficiency that are not symptomatic. Unfortunately, there has not been a randomized, double-blinded, placebo-controlled trial in patients with alpha-1 AT deficiency with and without symptoms.
    • A recent observational study compared the rate of decline in FEV1 in 97 Danish ex-smokers to 198 German ex-smokers, both of whom had severe alpha-1 AT deficiency. The German subjects received weekly infusions of 60 mg/kg alpha-1 AT, and the Danish did not receive augmentation therapy. The Germans had a slower rate of decline in their FEV1 as compared with the Danes (-53 ml/yr vs. -75 ml/yr, p=0.002).
    • Although weekly infusions are the only FDA approved regimen, monthly infusions (250 mg/kg) seem to have the same efficacy and safety and are widely used.
    • The ATS recommends augmentation therapy for patients with alpha-1 AT phenotypes PI ZZ, PI Z null or PI null null with alpha-1 AT levels < 11 umol/L and airflow obstruction.
    • It is crucial that these patients don’t smoke, and are treated with bronchodilators, just as other patients with airways obstruction. They should also receive pneumococcal and influenza vaccines.
    • A years worth of IV augmentation therapy costs approximately $25,000 - $35,000 (90% of which is for the drug).
    • There have not been any cases of HIV or hepatitis transmitted by pooled human alpha-1 AT.
    • Transplantation of both lungs and liver has been offered to patients with end stage disease. Liver transplantation has the added benefit of correcting the underlying disorder, as the new liver will produce and secrete alpha-1 AT. There is no data to support the use of augmentation therapy after lung transplantation, although some authors suggest augmentation therapy during times of increased neutrophil burden in the lung.

References

  1. Turner AM (2013). "Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies". BioDrugs. 27 (6): 547–58. doi:10.1007/s40259-013-0042-5. PMID 23771682.


Template:WikiDoc Sources